According to the IMS Institute for Healthcare Informatics, U.S. spending on drugs fell in 2012 for the first time since the group began reporting on prices in 1957. The decline was attributed to generic-drug utilization as patents expired on big-name treatments such as Plavix and Lipitor. Spending was $325.8 billion in 2012, a 1% drop from the previous year.

Related Summaries